Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2025 | Overweight | Morgan Stanley | |
| 3/12/2024 | Hold → Sell | Deutsche Bank | |
| 4/12/2023 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/3/2023 | Overweight → Equal-Weight | Morgan Stanley | |
| 2/16/2023 | Underweight → Equal Weight | Barclays | |
| 1/18/2023 | Hold → Buy | Jefferies | |
| 4/8/2022 | Equal-Weight | Morgan Stanley | |
| 11/5/2021 | Buy → Hold | Deutsche Bank |
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX®-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunodeficiencyA second trial, XPERT, will determine whether Grifols’ subcutaneous Ig, XEMBIFY® (immune globulin subcutaneous human klhw) is non-inferior to GAMUNEX-C in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Both studies are designed to support U.S. label expansion on these fast-growing Grifols Ig franchise therapies and offer patients more treatment options for their immune system disorders BARCELONA, Spain, July 16, 2026 (GLOBE NEWS
The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.FESILTY complements Grifols' bleeding management portfolio, expanding therapeutic options for patients. BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen defici
Chronos‑PD shows that biological changes associated with Parkinson's disease (PD) can emerge up to 12 years before clinical diagnosisUncovered reproducible early molecular signals and distinct molecular patterns in PD, supporting future efforts in patient stratification and precision medicine researchChronos is part of a broad Grifols program to find early disease biomarkers leveraging more than 100 million proprietary plasma samples connected to real-world data on thousands of conditions Grifols presents data in 13 posters and oral presentations at AD/PD™ 2026 conference in Copenhagen (Denmark) BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS
Morgan Stanley resumed coverage of Grifols, S.A. with a rating of Overweight
Deutsche Bank downgraded Grifols, S.A. from Hold to Sell
Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight
Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip
BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)
BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers
SC 13G/A - Grifols SA (0001438569) (Subject)
SC 13G/A - Grifols SA (0001438569) (Subject)
SC 13G - Grifols SA (0001438569) (Subject)